Joel Lewis Galectin Therapeutics Inc (GALT) insider trading activity

Joel Lewis is President and CEO of GALECTIN THERAPEUTICS INC. Currently has a direct ownership of 897,716 shares of GALT, which is worth approximately $781,012. The most recent transaction as insider was on Mar 01, 2024, when has been sold 152,584 shares (Common Stock) at a price of $1.96 per share, resulting in proceeds of $299,064. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 898K

0% 3M change

12.9% 12M change

Total Value Held $781,012

JOEL LEWIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2024	SELL Grant, award, or other acquisition	$299,064 $1.96 p/Share	152,584 Reduced 14.53%	897,716 Common Stock
Dec 29 2023	BUY Grant, award, or other acquisition	$19,265 $1.66 p/Share	11,606 Added 1.1%	1,042,300 Common Stock
Dec 15 2023	BUY Grant, award, or other acquisition	$19,267 $1.6 p/Share	12,042 Added 1.15%	1,030,694 Common Stock
Nov 30 2023	BUY Grant, award, or other acquisition	$19,266 $1.95 p/Share	9,880 Added 0.96%	1,018,652 Common Stock
Nov 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.87 p/Share	10,303 Added 1.01%	1,008,772 Common Stock
Oct 31 2023	BUY Grant, award, or other acquisition	$19,265 $2.04 p/Share	9,444 Added 0.94%	998,469 Common Stock
Oct 13 2023	BUY Grant, award, or other acquisition	$20,170 $2.01 p/Share	10,035 Added 1.0%	989,025 Common Stock
Sep 29 2023	BUY Grant, award, or other acquisition	$19,267 $1.92 p/Share	10,035 Added 1.01%	979,440 Common Stock
Sep 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.76 p/Share	10,947 Added 1.12%	969,405 Common Stock
Aug 31 2023	BUY Grant, award, or other acquisition	$19,267 $1.75 p/Share	11,010 Added 1.14%	958,458 Common Stock
Aug 15 2023	BUY Grant, award, or other acquisition	$19,267 $1.6 p/Share	12,042 Added 1.26%	947,448 Common Stock
Jul 31 2023	BUY Grant, award, or other acquisition	$19,266 $1.5 p/Share	12,844 Added 1.35%	935,406 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	$19,266 $1.63 p/Share	11,820 Added 1.27%	922,562 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$19,267 $1.44 p/Share	13,380 Added 93.63%	910 Common Stock
Jun 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.46 p/Share	13,196 Added 1.45%	897,362 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	$19,267 $1.57 p/Share	12,272 Added 1.37%	884,166 Common Stock
May 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.64 p/Share	11,748 Added 1.33%	871,894 Common Stock
Apr 28 2023	BUY Grant, award, or other acquisition	$19,266 $1.76 p/Share	10,947 Added 1.26%	860,146 Common Stock
Apr 14 2023	BUY Grant, award, or other acquisition	$19,265 $2.01 p/Share	9,585 Added 1.12%	849,199 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	$19,267 $2.1 p/Share	9,175 Added 1.08%	839,614 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	$19,266 $1.9 p/Share	10,140 Added 1.21%	830,439 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$156,345 $2.07 p/Share	75,529 Reduced 8.43%	820,299 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	$19,267 $2.07 p/Share	9,308 Added 1.03%	895,828 Common Stock
Feb 15 2023	BUY Grant, award, or other acquisition	$19,267 $1.44 p/Share	13,380 Added 1.49%	886,520 Common Stock
Feb 07 2023	BUY Grant, award, or other acquisition	$205,685 $1.43 p/Share	143,836 Added 14.14%	873,140 Common Stock

Joel Lewis

President and CEO

Norcross, GA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GALT shares.

Notify only if

Value

Insider Trading

Get notified when an Galectin Therapeutics Inc insider buys or sells GALT shares.

Notify only if

Operation

Value

Type

News

Receive news related to GALECTIN THERAPEUTICS INC

Track Activities on GALT

Account